Endacof HC and Pamidronate Disodium

• Generic Name: brompheniramine / hydrocodone / pseudoephedrine
• Dosage Forms: n.a.
• Other Brand Names: Bromplex HD, Endacof HC, Visvex, Drocon-CS, Anaplex HD, Bromph HD, BroveX HC, Bromcomp HC, J-Tan D HC, M-END, SymTan A

Brompheniramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Hydrocodone is a narcotic cough suppressant. It affects the signals in the brain that trigger cough reflex.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Endacof HC is a combination medicine used to treat runny or stuffy nose, sneezing, itching, watery eyes, cough, and sinus congestion caused by allergies, the common cold, or the flu.

Endacof HC will not treat a cough that is caused by smoking, asthma, or emphysema.

Endacof HC may also be used for purposes not listed in this medication guide.

• Generic Name: pamidronate
• Dosage Forms: n.a.
• Other Brand Names: Aredia

Used in conjunction with achievement and maintenance of adequate hydration for the treatment of moderate to severe hypercalcemia associated with malignant neoplasms, with or without bone metastases.

More conservative measures (e.g., hydration alone or combined with loop diuretics) generally used for treatment of mild or asymptomatic hypercalcemia. Corticosteroid therapy may be beneficial in hypercalcemia associated with hematological malignancies.

Consider retreatment in patients with recurrent or refractory disease.

Treatment of moderate to severe Paget’s disease of bone (osteitis deformans) in symptomatic patients with multiple bone involvement [polyostotic] and elevated concentrations of serum alkaline phosphatase and urinary hydroxyproline.

May prevent or slow progression of complications (e.g., deformities, arthritis, fractures, neurologic manifestations, spinal cord compression, heart failure) in patients with Paget’s disease of bone. May not reverse established complications (e.g., severe deformities, deafness).

Treatment in patients refractory to calcitonin or etidronate disodium.

Used as an adjunct to antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

Decreases the incidence and delays the development of bone-related complications (e.g., fractures or spinal cord compression, bone deterioration requiring radiotherapy or orthopedic surgery), and reduces bone pain and the need for supplemental analgesic therapy.